Krystal Biotech, Inc. KRYS
At closeNov 4, 2026, 4:55 AM EST
Pre-market · Nov 4, 4:55 AM ET
- YTD
- +23.72%
- 1 year
- +50.07%
- Market cap
- 9.04B
- Revenue (ttm)
- 470.02M
- Profit margin
- 47.91%
- EPS (ttm)
- 7.36
- Shares out
- 29.63M
- P/E ratio
- 41.44
- Forward P/E
- 33.89
- YTD return
- +23.72%
- 1-year return
- +50.07%
- Volume
- 603.05K
- Avg volume
- 272.85K
- Open
- 293.49
- Previous close
- 295.90
- Day's range
- 293.26 – 305.43
- 52-week range
- 192.52 – 382.54
- Beta
- 0.65
- Analysts
- Strong Buy
- Price target
- 393.56 (+29.0%)
- Earnings date
- Feb 16, 2027
2Y +134.18 (+78.54%)
Key statistics
- Enterprise value
- 7.87B
- PEG ratio
- 0.00
- Price / sales
- 19.23
- Price / book
- 6.30
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 30.20%
- Free cash flow
- 221.59M
- Total cash
- 911.85M
- Total debt
- 8.59M
- Return on equity
- 17.50%
- Short % of float
- 16.21%
- 50-day average
- 336.45
- 200-day average
- 308.60
Analyst view
Consensus: strong buy
- Target (low)
- 284.00
- Target (mean)
- 393.56
- Target (high)
- 474.00
- Strong buy1
- Buy10
- Hold1
- Sell0
- Strong sell0
Next earnings
Feb 16, 2027
Expected Feb 16, 2027. Consensus EPS estimate 2.65.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 16, 2027 | Dec 30, 2026 | 2.05 | — | — | — |
| Nov 2, 2026 | Sep 30, 2026 | 1.79 | 2.05 | +0.26 | +14.53% |
| Aug 3, 2026 | Jun 30, 2026 | 1.70 | 1.79 | +0.09 | +5.29% |
| May 4, 2026 | Mar 31, 2026 | 1.45 | 1.83 | +0.38 | +26.21% |
| Feb 17, 2026 | Dec 31, 2025 | 1.62 | 1.70 | +0.08 | +4.94% |
| Nov 3, 2025 | Sep 30, 2025 | 1.12 | 2.66 | +1.54 | +137.50% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 3, 2026 | Citigroup | main | Buy | Buy |
| Nov 3, 2026 | TD Cowen | main | Buy | Buy |
| Nov 3, 2026 | RBC Capital | main | Outperform | Outperform |
| Oct 15, 2026 | HC Wainwright & Co. | reit | Buy | Buy |
| Sep 21, 2026 | B of A Securities | main | Buy | Buy |
| Aug 14, 2026 | RBC Capital | init | — | Outperform |
About Krystal Biotech, Inc.
Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). It also develops KB803 for ocular complications of dystrophic epidermolysis bullosa; KB801 for neurotrophic keratitis; KB407, which is in Phase 1 clinical trials for treating cystic fibrosis; KB111 for Hailey-Hailey disease; KB707 for solid tumors; KB304 for dynamic wrinkles; KB707 that is in Phase 1/2 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- krystalbio.com
News
Citigroup Maintains Buy on Krystal Biotech, Lowers Price Target to $412 
TD Cowen Maintains Buy on Krystal Biotech, Lowers Price Target to $380 
RBC Capital Maintains Outperform on Krystal Biotech, Lowers Price Target to $375 
Krystal Biotech Analyst Says Stock Weakness 'Overblown' 
Krystal Biotech Analyst Says Stock Weakness 'Overblown' 
Krystal Biotech, Inc. (KRYS) Q3 2026 Earnings Call Transcript 
Krystal Biotech, Inc. (KRYS) Surpasses Q3 Earnings and Revenue Estimates 
Nasdaq Rallies as Tech Stocks Recover From Friday's Selloff 
Krystal Biotech Q3 Earnings Call Highlights 
Krystal Biotech Q3 2026 Earnings Call Transcript
Your note
Sign in to keep a note on KRYS — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| JANNEY DANIEL SPENCER | Director | Sale | Feb 26, 2026 | 0 |
| KRISHNAN KRISH S | Chief Executive Officer | Sale | Sep 3, 2026 | 1,565,250 |
| KRISHNAN SUMA M | Officer, Director and Beneficial Owner | Sale | Sep 3, 2026 | 1,493,160 |
| ROMANO KATHRYN | Officer | Sale | Mar 1, 2026 | 22,366 |
| ROSSI DINO A | Director | Stock Gift | Aug 13, 2026 | 50,000 |
| THOMAS JOHN CHARLES MICHAEL | General Counsel | Sale | Jun 24, 2026 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| FMR, LLC | 14.93% | 4,418,197 | 1.35B | Jun 29, 2026 |
| Blackrock Inc. | 14.13% | 4,181,432 | 1.28B | Jun 29, 2026 |
| Avoro Capital Advisors LLC | 9.76% | 2,888,888 | 881.20M | Jun 29, 2026 |
| Vanguard Portfolio Management LLC | 5.32% | 1,574,905 | 480.39M | Jun 29, 2026 |
| State Street Corporation | 4.56% | 1,351,158 | 412.14M | Jun 29, 2026 |
| Vanguard Capital Management LLC | 4.19% | 1,240,567 | 378.41M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Select Portfolios-Select Biotechnology Portfolio | 6.09% | 1,802,622 | 549.85M | Aug 30, 2026 |
| iShares Trust-iShares Core S&P Mid-Cap ETF | 3.21% | 948,897 | 289.44M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 3.01% | 889,548 | 271.34M | Jun 29, 2026 |
| Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund | 2.76% | 816,132 | 248.94M | Aug 30, 2026 |
| SmallCap World Fund Inc | 2.54% | 752,244 | 229.46M | Sep 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 2.28% | 675,066 | 205.92M | Sep 29, 2026 |